BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-122@catalystbrief.girapphe.com
DTSTAMP:20261117T181556Z
LAST-MODIFIED:20261117T181556Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Boehringer Ingelheim — BI 690517 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: EASi-KIDNEY™ (The Studies of Hear
 t & Kidney Protection With BI 690517 in Combination With Empagliflozin).\n
 Source: https://clinicaltrials.gov/study/NCT06531824\nhttps://catalystbrie
 f.girapphe.com/e/122?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/122?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
